Effect of berberine on p53 expression by TPA in breast cancer cells

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 210-215

  Kim, Sangmin ^a   Han, Jeonghun ^a   Kim, Nam Young ^a   Lee, Se Kyung ^a   Cho, Dong Hui ^a   Choi, Min Young ^a   Kim, Jee Soo ^a   Kim, Jung Han ^a   Choe, Jun Ho ^a   Nam, Seok Jin ^a   Lee, Jeong Eon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Berberine; Lysosome; p53; Proteasome

Indexed keywords

ALLN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BERBERINE; CHLOROQUINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHRONOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LYSOSOME; MUTANT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BERBERINE; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOGENS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855273572     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1480     Document Type: Article

References (30)

1. Ikram M: A review on the chemical and pharmacological aspects of genus Berberis. Planta Med 28: 353-358, 1975.
2. Anis KV, Rajeshkumar NV and Kuttan R: Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53: 763-768, 2001. (Pubitemid 32457828)
3. Chi CW, Chang YF, Chao TW, et al.: Flow cytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci 54: 2099-2107, 1994.
4. Kuo CL, Chou CC and Yung BY: Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett 93: 193-200, 1995.
5. Kim S, Choi MG, Lee HS, et al.: Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules 14: 4300-4311, 2009.
6. Kim S, Kim Y, Kim JE, Cho KH and Chung JH: Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine 15: 340-347, 2008. (Pubitemid 351508395)
7. Kim S, Choi JH, Kim JB, et al.: Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules 13: 2975-2985, 2008.
8. Kim S and Chung JH: Berberine prevents UV-induced MMP-1 and reduction of type I procollagen expression in human dermal fibroblasts. Phytomedicine 15: 749-753, 2008.
9. Woods DB and Vousden KH: Regulation of p53 function. Exp Cell Res 264: 56-66, 2001. (Pubitemid 32989081)
10. Lacroix M, Toillon RA and Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 13: 293-325, 2006. (Pubitemid 43886660)
11. Momand J, Wu HH and Dasgupta G: MDM2-master regulator of the p53 tumor suppressor protein. Gene 242: 15-29, 2000. (Pubitemid 30064488)
12. Colman MS, Afshari CA and Barrett JC: Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 462: 179-188, 2000. (Pubitemid 30190225)
13. Sugrue MM, Shin DY, Lee SW and Aaronson SA: Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 94: 9648-9653, 1997. (Pubitemid 27408116)
14. Royds JA and Iacopetta B: p53 and disease: when the guardian angel fails. Cell Death Differ 13: 1017-1026, 2006.
15. Sur S, Pagliarini R, Bunz F, et al.: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964-3969, 2009.
16. Petitjean A, Mathe E, Kato S, et al.: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007. (Pubitemid 46744292)
17. Dittmer D, Pati S, Zambetti G, et al.: Gain of function mutations in p53. Nat Genet 4: 42-46, 1993. (Pubitemid 23165910)
18. Hsiao M, Low J, Dorn E, et al.: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145: 702-714, 1994. (Pubitemid 24285977)
19. Liu Z, Liu Q, Xu B, et al.: Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res 662: 75-83, 2009.
20. Choi MS, Oh JH, Kim SM, et al.: Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 34: 1221-1230, 2009.
21. Zhang X, Gu L, Li J, et al.: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 70: 9895-9904, 2010.
22. Bond GL, Hu W, Bond EE, et al.: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004. (Pubitemid 39535748)
23. Kim JB, Lee KM, Ko E, et al.: Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231. Planta Med 74: 39-42, 2008. (Pubitemid 351251381)
24. Datta R, Yoshinaga K, Kaneki M, Pandey P and Kufe D: Phorbol ester-induced generation of reactive oxygen species is protein kinase cbeta-dependent and required for SAPK activation. J Biol Chem 275: 41000-41003, 2000. (Pubitemid 32054926)
25. Shimao Y, Nabeshima K, Inoue T and Koono M: TPA-enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC downregulation and antisense oligonucleotides treatment. Clin Exp Metastasis 17: 351-360, 1999. (Pubitemid 29477581)
26. Schlingemann J, Hess J, Wrobel G, et al.: Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 104: 699-708, 2003. (Pubitemid 36418506)
27. Woo JH, Lim JH, Kim YH, et al.: Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23: 1845-1853, 2004. (Pubitemid 38445410)
28. Woo JH, Park JW, Lee SH, et al.: Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor kappa B transcriptional activity. Cancer Res 63: 3430-3434, 2003.
29. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
30. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.31. Mantovani F and Banks L: Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 18: 3309-3315, 1999.